Trastuzumab-Induced Cardiomyopathy

Maya Guglin, Raymond Cutro, Joseph D. Mishkin

Research output: Contribution to journalReview article

53 Scopus citations

Abstract

Trastuzumab is a recombinant humanized monoclonal antibody used for the treatment of advanced breast cancer. It improves survival and increases response to chemotherapy. The major side effect of trastuzumab is cardiotoxicity manifesting as a reduction in left ventricular systolic function, either asymptomatic or with signs and symptoms of heart failure. Although reversible in most cases, cardiotoxicity frequently results in the discontinuation of trastuzumab. The objective of this review is to summarize facts about trastuzumab-induced cardiotoxicity and to highlight the areas of future investigations. We searched PubMed for trials involving trastuzumab used as an adjuvant therapy for breast cancer, including the metastatic breast cancer setting, and focused on cardiotoxicity.

Original languageEnglish (US)
Pages (from-to)437-444
Number of pages8
JournalJournal of Cardiac Failure
Volume14
Issue number5
DOIs
StatePublished - Jun 1 2008

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Trastuzumab-Induced Cardiomyopathy'. Together they form a unique fingerprint.

  • Cite this